Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Modulation of the antagonistic properties of an insulin mimetic peptide by disulfide bridge modifications

M. Lubos, J. Pícha, I. Selicharová, J. Žák, M. Buděšínský, K. Mitrová, L. Žáková, J. Jiráček

. 2023 ; 29 (7) : e3478. [pub] 20230125

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23010959

Grantová podpora
MR/R009066/1 Medical Research Council - United Kingdom

Insulin is a peptide responsible for regulating the metabolic homeostasis of the organism; it elicits its effects through binding to the transmembrane insulin receptor (IR). Insulin mimetics with agonistic or antagonistic effects toward the receptor are an exciting field of research and could find applications in treating diabetes or malignant diseases. We prepared five variants of a previously reported 20-amino acid insulin-mimicking peptide. These peptides differ from each other by the structure of the covalent bridge connecting positions 11 and 18. In addition to the peptide with a disulfide bridge, a derivative with a dicarba bridge and three derivatives with a 1,2,3-triazole differing from each other by the presence of sulfur or oxygen in their staples were prepared. The strongest binding to IR was exhibited by the peptide with a disulfide bridge. All other derivatives only weakly bound to IR, and a relationship between increasing bridge length and lower binding affinity can be inferred. Despite their nanomolar affinities, none of the prepared peptide mimetics was able to activate the insulin receptor even at high concentrations, but all mimetics were able to inhibit insulin-induced receptor activation. However, the receptor remained approximately 30% active even at the highest concentration of the agents; thus, the agents behave as partial antagonists. An interesting observation is that these mimetic peptides do not antagonize insulin action in proportion to their binding affinities. The compounds characterized in this study show that it is possible to modulate the functional properties of insulin receptor peptide ligands using disulfide mimetics.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23010959
003      
CZ-PrNML
005      
20230801132728.0
007      
ta
008      
230718s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1002/psc.3478 $2 doi
035    __
$a (PubMed)36633503
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Lubos, Marta $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Praha, Czech Republic
245    10
$a Modulation of the antagonistic properties of an insulin mimetic peptide by disulfide bridge modifications / $c M. Lubos, J. Pícha, I. Selicharová, J. Žák, M. Buděšínský, K. Mitrová, L. Žáková, J. Jiráček
520    9_
$a Insulin is a peptide responsible for regulating the metabolic homeostasis of the organism; it elicits its effects through binding to the transmembrane insulin receptor (IR). Insulin mimetics with agonistic or antagonistic effects toward the receptor are an exciting field of research and could find applications in treating diabetes or malignant diseases. We prepared five variants of a previously reported 20-amino acid insulin-mimicking peptide. These peptides differ from each other by the structure of the covalent bridge connecting positions 11 and 18. In addition to the peptide with a disulfide bridge, a derivative with a dicarba bridge and three derivatives with a 1,2,3-triazole differing from each other by the presence of sulfur or oxygen in their staples were prepared. The strongest binding to IR was exhibited by the peptide with a disulfide bridge. All other derivatives only weakly bound to IR, and a relationship between increasing bridge length and lower binding affinity can be inferred. Despite their nanomolar affinities, none of the prepared peptide mimetics was able to activate the insulin receptor even at high concentrations, but all mimetics were able to inhibit insulin-induced receptor activation. However, the receptor remained approximately 30% active even at the highest concentration of the agents; thus, the agents behave as partial antagonists. An interesting observation is that these mimetic peptides do not antagonize insulin action in proportion to their binding affinities. The compounds characterized in this study show that it is possible to modulate the functional properties of insulin receptor peptide ligands using disulfide mimetics.
650    12
$a inzulin $x metabolismus $7 D007328
650    12
$a receptor inzulinu $7 D011972
650    _2
$a disulfidy $x chemie $7 D004220
650    _2
$a peptidy $x chemie $7 D010455
655    _2
$a časopisecké články $7 D016428
700    1_
$a Pícha, Jan $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Praha, Czech Republic
700    1_
$a Selicharová, Irena $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Praha, Czech Republic
700    1_
$a Žák, Jíří $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Praha, Czech Republic
700    1_
$a Buděšínský, Miloš $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Praha, Czech Republic
700    1_
$a Mitrová, Katarína $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Praha, Czech Republic
700    1_
$a Žáková, Lenka $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Praha, Czech Republic
700    1_
$a Jiráček, Jiří $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Praha, Czech Republic
773    0_
$w MED00002886 $t Journal of peptide science : an official publication of the European Peptide Society $x 1099-1387 $g Roč. 29, č. 7 (2023), s. e3478
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36633503 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801132724 $b ABA008
999    __
$a ok $b bmc $g 1963405 $s 1197224
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 29 $c 7 $d e3478 $e 20230125 $i 1099-1387 $m Journal of peptide science $n J Pept Sci $x MED00002886
GRA    __
$a MR/R009066/1 $p Medical Research Council $2 United Kingdom
LZP    __
$a Pubmed-20230718

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...